Onyx floats $359m stock offer to finance Kyprolis, oprozomib and R&D
This article was originally published in Scrip
Executive Summary
Onyx Pharmaceuticals is selling 4.4 million shares of common stock to raise gross proceeds of $358.6 million for the commercialization of the third-line multiple myeloma drug Kyprolis (carfilzomib) and for the South San Francisco-based company's ongoing clinical trials to support registration and expansion of new and approved cancer therapies.